UNSPSC 51352436: Ethinylestradiol/cyproterone acetate

Ethinylestradiol/cyproterone acetate (EE/CPA), also known as co-cyprindiol is a combination of ethinylestradiol (EE), an estrogen, and cyproterone acetate (CPA), a progestin and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.

UNSPSC 51352436 Ethinylestradiol/cyproterone acetate is a Commodity code that nominally describes a specific hormonal pharmaceutical product, but recent state and local procurement activity under this code does not align with the code's pharmaceutical specificity. The available recent opportunities show no solicitations for ethinylestradiol/cyproterone acetate or related oral contraceptive products. Instead, the code has been applied to a mix of unrelated state and local notices, including a county purchasing department relocation announcement (Williamson County, Texas, July 2026), a reverse trade show event (Marion County, Florida, June 2026), a vendor forum (Williamson County, Texas, March 2026), and a vendor open house (Indian River County, Florida, February 2026). None of these entries represent actual product procurement or represent relevant sourcing activity for firms seeking pharmaceutical supply contracts.

The only substantive pharmaceutical procurement posted under or near this code family is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (January 2026, response due March 26, 2026), which solicits multiple manufacturers to supply identified drugs through authorized wholesalers across participating state and local government facilities, including Oregon. This is a cooperative purchasing vehicle requiring vendors to maintain relationships with at least two of three specified wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and to submit detailed product information by NDC code, with pricing weighted at 75 percent of evaluation. Vendors must certify cGMP and DSCSA compliance, carry $5 million commercial general liability coverage, and accept a 3 percent administrative fee. The code itself carries minimal recent activity relevant to direct pharmaceutical contracting at the state and local level; the mismatch between the code's specific product scope and the notices posted under it suggests either miscoding of opportunities or infrequent procurement of this particular formulation in state and local markets.